Santhera Licenses Melanocortin-4 Receptor Antagonist Program to BioLineRx
Santhera Pharmaceuticals announced an exclusive license agreement with BioLineRx, covering Santhera's pre-clinical melanocortin-4 receptor (MC-4R) antagonist program currently in development for the treatment of cancer cachexia. Under the agreement, BioLineRx acquires all rights to develop, sub-license and commercialize the compound. BioLineRx will cover all future costs of the program. Santhera will receive 22% to 25% of all BioLineRx's sub-licensing income or royalties on future sales by BioLineRx. The out-licensing deal is in line with Santhera's strategy to focus on its core late stage or marketed assets: Catena®, fipamezole and omigapil.
The preclinical activity spectrum of orally active MC-4R antagonists indicates beneficial efficacy in all key aspects of cachexia such as lack of appetite, increased resting energy expenditure and enhanced catabolism. The latest generation of compounds increased food intake 3- to 5-fold and inhibited the development of cachexia in a disease-relevant animal tumor model.
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
CyGenics Expands Into Europe - Plans to acquire stake in PharmaCell
Addex Partner Starts First-Ever Clinical Trial of an mGluR Positive Allosteric Modulator - Novel Approach Has Potential for Treatment of Multiple CNS Disorders
Summit is new name for VASTox
Allon Therapeutics completes enrolment for Phase II Alzheimer's trial
Organon and Schering to continue research in male fertility control separately
GPC Biotech AG Named in Purported Class Action Lawsuit in the United States
